Table 4.

Summary of testing with in vitro assays on longitudinal series of blood samples from BSE-infected recipient sheep

AssayNo. of positive samples/no. of samples tested (% positive samples)
TP1
6 mpi
TP2
9 mpi
TP3
12 mpi
TP4
18-25 mpi
TP5
32 mpi
TP6 (terminal)15-36 mpi
mb-PMCA 9/10 (90%) 10/10 (100%) 10/10 (100%) 3/4 (75%) 1/1 (100%) 9/9 (100%) 
capture-PMCA 8/10 (80%) 10/10 (100%) 10/10 (100%) 3/4 (75%) 1/1 (100%) 9/9 (100%) 
WB IOME RT-QuIC 7/10 (70%) 8/10 (80%) 9/10 (90%) 3/4 (75%) 1/1 (100%) 6/9 (67%) 
AssayNo. of positive samples/no. of samples tested (% positive samples)
TP1
6 mpi
TP2
9 mpi
TP3
12 mpi
TP4
18-25 mpi
TP5
32 mpi
TP6 (terminal)15-36 mpi
mb-PMCA 9/10 (90%) 10/10 (100%) 10/10 (100%) 3/4 (75%) 1/1 (100%) 9/9 (100%) 
capture-PMCA 8/10 (80%) 10/10 (100%) 10/10 (100%) 3/4 (75%) 1/1 (100%) 9/9 (100%) 
WB IOME RT-QuIC 7/10 (70%) 8/10 (80%) 9/10 (90%) 3/4 (75%) 1/1 (100%) 6/9 (67%) 

Please note time points TP1-TP5 are preclinical: clinical signs of BSE were evident only at TP6 (terminal).

Twenty-five mpi sample from sheep P453 tested negative by all 3 in vitro assays, despite earlier and subsequent time points testing positive (also see supplemental Figures 2-4); the reason for this apparently anomalous result could not be determined.

or Create an Account

Close Modal
Close Modal